Orion Therapeutics develops RNA therapeutics using its proprietary GENESYS™ delivery platform, which utilizes bio-inspired lipopeptides to package and deliver RNA payloads without ionizable cationic lipids. This technology enables targeted treatment of vascular diseases by enhancing the therapeutic index and accessing previously unreachable areas of the body.
Funding
$500K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current RNA therapies face challenges in delivering RNA payloads effectively and safely to target cells, often relying on delivery systems with limited targeting capabilities and potential for immune activation. This can result in reduced therapeutic efficacy and increased risk of adverse effects, hindering the development of RNA-based treatments for a wide range of diseases.
Solution
Orion Therapeutics is developing next-generation RNA medicines using its proprietary GENESYS™ LNP delivery platform, which enables efficient and safe delivery of RNA payloads to target cells anywhere in the body. The GENESYS™ platform incorporates bio-inspired lipopeptides and excludes ionizable cationic lipids entirely, enhancing cellular uptake and improving the therapeutic index. This targeted delivery system is payload-agnostic and can be modified for various disease indications, including vascular diseases, by delivering siRNA and mRNA drug payloads.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing RNA therapeutics, particularly for vascular diseases and other indications where targeted delivery and reduced immunogenicity are critical.
Features
- Proprietary LNP delivery platform that excludes ionizable lipids for precise and targeted delivery of RNA therapeutics
- Bio-inspired lipopeptide technology to enhance cellular uptake and targeting
- Reduced immunogenicity compared to ionizable LNPs, promoting safer clinical profiles
- Scalable production using state-of-the-art microfluidic technologies for consistent nanoparticle quality
- Intellectual property protection covering lipopeptide-based compositions, formulation processes, and targeted delivery
- Agnostic to nucleic acid payload, adaptable to various forms of RNA for treatment of many diseases across the body